3-氨基-1H-吡唑并[3,4-b]吡啶 | 6752-16-5

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 中文名称: 3-氨基-1H-吡唑并[3,4-b]吡啶
• 中文别名: 1H-吡唑并[3,4-B]吡啶-3-胺；1H-吡唑[3,4]吡啶-3-胺；3-氨基吡唑并[3,4-B]吡啶；3-氨基-1H-吡唑并[3,4b]吡啶；3-氨基吡唑并[3,4-b]吡啶；1H-吡唑O[3,4-B]砒啶-3-胺；1H-吡唑并[3,4-b]吡啶-3-胺
• 英文名称: 1H-pyrazolo[3,4-b]pyridin-3-amine
• 英文别名: 3-amino-1H-pyrazolo[3,4-b]pyridine；2H-pyrazolo[3,4-b]pyridin-3-amine
• CAS: 6752-16-5
• 化学式: C₆H₆N₄
• mdl: MFCD04113611
• 分子量: 134.14
• InChiKey: LUAQTQAFUORQHV-UHFFFAOYSA-N

物化性质

• 熔点：
  189-192°C
• 沸点：
  315.3±25.0 °C(Predicted)
• 密度：
  1.61±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于二甲基亚砜、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.6
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S45
• 危险类别码：
  R25
• WGK Germany：
  1,3
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  | 冰箱 |

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 3-Amino-7-azaindazole
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 6752-16-5
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 3), H301
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
T Toxic R25
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H301 Toxic if swallowed.
Precautionary statement(s)
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C6H6N4
Molecular Weight : 134,14 g/mol
CAS-No. : 6752-16-5
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
3-AMINO-7-AZAINDAZOLE
Acute Tox. 3; H301 -
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
3-AMINO-7-AZAINDAZOLE
T, R25 -
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Store under nitrogen.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N99 (US) or type P2 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 187 - 192 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 0,634
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 2811 IMDG: 2811 IATA: 2811
UN proper shipping name
ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. (3-AMINO-7-AZAINDAZOLE)
IMDG: TOXIC SOLID, ORGANIC, N.O.S. (3-AMINO-7-AZAINDAZOLE)
IATA: Toxic solid, organic, n.o.s. (3-AMINO-7-AZAINDAZOLE)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
H301 Toxic if swallowed.
Full text of R-phrases referred to under sections 2 and 3
T Toxic
R25 Toxic if swallowed.
Further information
Copyright 2013 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  3-氨基-1H-吡唑并[3,4-b]吡啶 在 盐酸 、 甲酸 、 溶剂黄146 、 sodium nitrite 、 二氧化硫 、 copper dichloride 作用下， 以 水 为溶剂， 反应 0.25h， 生成 1H-pyrazolo[3,4-b]pyridine-3-sulfonyl chloride
  参考文献：
  名称：

  WO2007/59219

  摘要：

  公开号：
• 作为产物：
  描述：

  3-硝基-1H-吡唑并[3,4-B]吡啶 在 盐酸 、 tin(II) chloride dihdyrate 作用下， 以 水 为溶剂， 反应 0.5h， 生成 3-氨基-1H-吡唑并[3,4-b]吡啶
  参考文献：
  名称：

  探索氮杂环支架用于开发强效人中性粒细胞弹性蛋白酶抑制剂

  摘要：

  人中性粒细胞弹性蛋白酶 (HNE) 是一种强效蛋白酶，在许多过程中发挥重要的生理作用，但也参与影响肺系统的各种病理。因此，能够抑制 HNE 蛋白水解活性的化合物可以代表有效的治疗方法。我们在此展示了一系列新的吡唑并吡啶和吡咯并吡啶衍生物作为 HNE 抑制剂，设计为我们先前合成的吲唑和吲哚的修饰，以评估氮位置变化和/或在支架中插入额外氮的影响生物活性和化学稳定性。我们获得了具有 IC 50的强效 HNE 抑制剂值在低纳摩尔范围（10-50 nM），一些化合物在磷酸盐缓冲液中表现出改善的化学稳定性（t 1/2 > 6 h）。分子模型研究表明，抑制活性严格依赖于 HNE Ser195 的 OH 基团与抑制剂的羰基碳之间形成的米氏复合物。此外，计算机ADMET 计算预测大多数新化合物将被最佳吸收、分布、代谢和排泄。因此，这些新的和有效的 HNE 抑制剂代表了未来治疗发展的新线索。

  DOI：

  10.1016/j.bmc.2020.115836

文献信息

• [EN] AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF<br/>[FR] AZAINDAZOLES COMME MODULATEURS DE LA KINASE BTK ET LEUR UTILISATION
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011019780A1

  公开（公告）日：2011-02-17

  Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, (I) are useful as kinase modulators, including Btk modulation, wherein A1, A2, A3, R4, are as defined herein.

  具有化学式(I)的化合物，以及其对映体、非对映异构体、药用可接受的盐，(I)可用作激酶调节剂，包括Btk调节，在此处定义了A1、A2、A3、R4。
• Compounds as syk kinase inhibitors
  申请人：Almirall, S.A.

  公开号：EP2489663A1

  公开（公告）日：2012-08-22

  The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase.

  本发明涉及一种化合物（I）的公式，以及制备这种化合物的方法，以及它们在治疗病理状况或疾病中的应用，这些病理状况或疾病容易通过抑制Syk激酶而得到改善。
• 一种嘧啶并吲唑类化合物的合成方法
  申请人：新乡医学院

  公开号：CN109912606B

  公开（公告）日：2021-05-04

  本发明公开了一种嘧啶并吲唑类化合物的合成方法，属于有机合成技术领域。本发明的技术方案要点为：一种嘧啶并吲唑类化合物的合成方法，具体步骤为：将芳香醛类化合物、3‑氨基吲唑类生物和三乙胺溶于溶剂中，再加入NH4I和氧化剂，然后于110‑150℃反应制得目标产物嘧啶并吲唑类化合物。本发明合成过程简单高效，通过无过渡金属催化的一锅串联反应一步直接制得嘧啶并吲唑类化合物，避免了由于多步反应中多种试剂的使用以及对各步反应中间体的纯化处理等引起的资源浪费和环境污染，合成过程操作方便，原料简单，反应条件温和，底物适用范围广，同时以三乙胺为原料极大地降低了生产成本。
• Aerobic α,β-C(sp³)–H Bond Difunctionalization and C–N Bond Cleavage of Triethylamine: Difunctional Ammonium Iodide Enabling the Regioselective Synthesis of 4-Arylpyrimido[1,2-<i>b</i>]indazoles
  作者：Qinghe Gao、Xinya Han、Peiyuan Tong、Zhiang Zhang、Haotian Shen、Yanrong Guo、Suping Bai

  DOI：10.1021/acs.orglett.9b02218

  日期：2019.8.2

  A novel method for the regioselective synthesis of 4-arylpyrimido[1,2-b]indazoles has been developed via the dual C(sp3)–H bond functionalization and C–N bond cleavage of triethylamine. The elusive acyclic enamine intermediates are effectively in situ generated and captured by aromatic aldehydes to form a wide array of tricyclic products from 3-aminoindazoles under the NH4I-mediated aerobic oxidative

  通过三乙胺的双C（sp 3）-H键官能化和C-N键裂解，开发了一种新的区域选择性合成4-芳基嘧啶[1,2- b ]吲唑的新方法。难以捉摸的无环烯胺中间体可在NH 4 I介导的需氧氧化条件下有效地原位生成并被芳族醛捕获，从而形成多种由3-氨基吲唑形成的三环产物。该反应具有容易获得的原料，绿色和经济条件以及有价值的产品的特点。
• [EN] PROCESS FOR PREPARING 5-FLUORO-1H-PYRAZOLO [3, 4-B] PYRIDIN-3-AMINE AND DERIVATIVES THEREOF<br/>[FR] PROCÉDÉ DE PRÉPARATION DE LA 5-FLUORO-1H-PYRAZOLO[3,4-B]PYRIDIN-3-AMINE ET DES DÉRIVÉS DE CELLE-CI
  申请人：VERTEX PHARMA

  公开号：WO2009018415A1

  公开（公告）日：2009-02-05

  The present invention relates to a process for the synthesis of 5-fluoro-1H-pyrazolo [3, 4-b]pyridin-3-amine in high yield and purity. The present invention also relates to processes for the synthesis of 5-fluoro-1H-pyrazolo [3, 4- b] ρyridin-3-amine derivatives. These processes are useful for preparing biologically active compounds, particularly certain GSK-3 inhibitors, or derivatives thereof. Reagents and conditi ons : i. Pd ( OAc )2, PPh3, Et3N, H2CO2; i i. 1 ) (COCl )2, CH2Cl2, cat. DMF; 2 ) NH3 (g ), dioxane, i i i. TFAA, Et3N, CH2Cl2, O°C; iv. H2NNH2. H2O, n-butanol, reflux.

  本发明涉及一种高产率和纯度合成5-氟-1H-吡唑并[3,4-b]吡啶-3-胺的方法。本发明还涉及合成5-氟-1H-吡唑并[3,4-b]吡啶-3-胺衍生物的方法。这些方法适用于制备生物活性化合物，特别是某些GSK-3抑制剂或其衍生物。试剂和条件：i. Pd(OAc)2，PPh3，Et3N，H2CO2；ii. 1) (COCl)2，CH2Cl2，催化剂DMF；2) NH3(g)，二恶烷，iii. TFAA，Et3N，CH2Cl2，0°C；iv. H2NNH2，H2O，正丁醇，回流。